Stablizing An Enzyme By Forming A Mixture, An Adduct Or A Composition, Or Formation Of An Adduct Or Enzyme Conjugate Patents (Class 435/188)
-
Publication number: 20150147276Abstract: The invention provides compositions and methods for targeted controlled drug release. The compositions and methods can be used for treating or imaging vascular stenosis, stenotic lesions, occluded lumens, embolic phenomena, thrombotic disorders and internal hemorrhage.Type: ApplicationFiled: June 7, 2013Publication date: May 28, 2015Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Donald E. Ingber, Netanel Korin, Mathumai Kanapathipilai, Oktay Uzun, Anne-Laure Papa
-
Publication number: 20150147798Abstract: Provided are: a method for stabilizing an ascorbic acid oxidase; a method for preserving an ascorbic acid oxidase; and a stabilized composition of an ascorbic acid oxidase. A method for stabilizing an ascorbic acid oxidase and a method for preserving an ascorbic acid oxidase, each of the methods comprising allowing an ascorbic acid oxidase to coexist with nitrous acid or a salt thereof, or a nitrous acid ester in an aqueous medium; and a stabilized composition of an ascorbic acid oxidase, which comprises an ascorbic acid oxidase being allowed to coexist with nitrous acid or a salt thereof, or a nitrous acid ester in an aqueous medium. The method for stabilizing an ascorbic acid oxidase, the method for preserving an ascorbic acid oxidase, and the stabilized composition of an ascorbic acid oxidase according to the present invention are useful for clinical diagnosis and the like.Type: ApplicationFiled: May 23, 2013Publication date: May 28, 2015Inventors: Kenta Kinjo, Tomoko Aratake
-
Patent number: 9040274Abstract: The invention provides a simple and effective method for increasing thermal stability of a wide range of proteins, comprising fusing a self-assembling amphipathic peptide to the C- or N-terminal of target proteins. The fusion protein can have a half life up to 26 times longer than that of the wild type protein.Type: GrantFiled: April 25, 2013Date of Patent: May 26, 2015Assignee: Jiangnan UniversityInventors: Jian Chen, Guocheng Du, Xinyao Lu, Song Liu, Juan Zhang
-
Publication number: 20150140001Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clecl4a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clecl4a as an epitope for an antibody suppressive of angiogenesis.Type: ApplicationFiled: June 14, 2013Publication date: May 21, 2015Applicant: SCRIPPS KOREA ANTIBODY INSTITUTEInventors: Suk Mook Lee, Min kyoung Ki, Mee Hyun Jeoung, Jong Rip Choi
-
Publication number: 20150140572Abstract: The present invention relates to a composition having the activity of degrading the cell wall of a Mycobacterium species comprising: (a) a first fusion protein including (i) a domain with a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, D-Ala-m-DAP (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase, (ii) at least one peptide stretch fused to the N- or C-terminus of the domain with the first enzymatic activity; and (iii) a protein transduction domain (PTD) being at the N- or C-terminus of the first fusion protein; and (b) a second fusion protein including (i) a domain with a second enzymatic activity, the enzymatic activity being at least one or more of the following: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hyType: ApplicationFiled: July 1, 2013Publication date: May 21, 2015Inventors: Stefan Miller, Robert Andreas Fischer
-
Publication number: 20150140549Abstract: Described herein are aqueous soluble polymersomes that encapsulate one or more hydrophobic fluorescent polymers and methods of their preparation and use.Type: ApplicationFiled: September 30, 2014Publication date: May 21, 2015Inventors: Majid MEHRPOUYAN, Shumeye MAMO, Marybeth SHARKEY
-
Publication number: 20150140022Abstract: A compound comprising a photosensitizer covalently coupled to a protein selected from the group consisting of antibodies or their derivatives or fragments thereof, synthetic peptides such as scFv, mimotopes which bind CD antigens, cytokine receptors, interleukin receptors, hormone receptors, growth factor receptors, more particularly tyrosine kinase growth factor receptor of the ErbB family, wherein the photosensitizer is coupled to the binding protein via O6-alkylguanine-DNA alkyltransferase (hAGTm), a modified human DNA repair protein.Type: ApplicationFiled: March 21, 2012Publication date: May 21, 2015Inventors: Stefan Barth, Mehmet K. Tur, Ahmad Hussain
-
Patent number: 9034321Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: GrantFiled: May 3, 2011Date of Patent: May 19, 2015Assignees: aTyr Pharma, Inc., Pangu BioPharma LimitedInventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
-
Patent number: 9034318Abstract: The invention provides reagents and methods for enzyme replacement therapy using chemically modified species of human cystathionine ?-synthase (CBS) to treat homocystinuria and other related diseases and disorders.Type: GrantFiled: March 14, 2013Date of Patent: May 19, 2015Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: Jan P Kraus, Tomas Majtan, Erez Bublil
-
Patent number: 9034320Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: GrantFiled: April 29, 2011Date of Patent: May 19, 2015Assignees: aTyr Pharma, Inc., Pangu BioPharma LimitedInventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry Dean Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
-
Patent number: 9034624Abstract: The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.Type: GrantFiled: June 4, 2010Date of Patent: May 19, 2015Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Matteo D'Este, Davide Renier, Gianfranco Pasut, Antonio Rosato
-
Patent number: 9029321Abstract: Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo.Type: GrantFiled: March 30, 2012Date of Patent: May 12, 2015Assignee: Board of Regents of the University of TexasInventors: Mikhail G. Kolonin, Alexes Daquinag, Yan Zhang
-
Publication number: 20150125423Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: January 12, 2015Publication date: May 7, 2015Inventors: Jennifer Mitcham, Matthew Moyle
-
Publication number: 20150125876Abstract: The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27.Type: ApplicationFiled: December 24, 2014Publication date: May 7, 2015Applicant: MCBI INC.Inventors: Kazuhiko UCHIDA, Kohji MENO, Hideaki SUZUKI
-
Publication number: 20150125437Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.Type: ApplicationFiled: January 16, 2015Publication date: May 7, 2015Inventors: Shawn Defrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneerselvam
-
Publication number: 20150125445Abstract: The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.Type: ApplicationFiled: June 13, 2013Publication date: May 7, 2015Inventors: John C. Herr, Eusebio S. Pires, Austin Herr
-
Publication number: 20150126387Abstract: A method for screening an AMPK activator, wherein inhibition of an interaction between prohibitin and AMPK is used as an index is provided. Besides, an AMPK activator comprising, as an active ingredient, a compound inhibiting an interaction between prohibitin and AMPK, and a prohibitin-AMPK complex are also provided.Type: ApplicationFiled: May 16, 2013Publication date: May 7, 2015Applicant: Kyorin Pharmaceutical Co., Ltd.Inventors: Tomohiro Ide, Naoki Kobayashi, Yunike Akasaka, Takashi Komine, Koji Murakami
-
Publication number: 20150118252Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.Type: ApplicationFiled: June 13, 2013Publication date: April 30, 2015Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
-
Publication number: 20150118731Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: ApplicationFiled: November 7, 2014Publication date: April 30, 2015Applicants: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Rob LAVIGNE, Stefan MILLER, Yves BRIERS, Guido VOLCKAERT, Maarten WALMAGH
-
Publication number: 20150118730Abstract: The present invention is directed to enzyme based methods for separating protein from protein-rich materials derived from plant seeds, fruit, or other biomass and products made therefrom. The protein content in the resulting products is improved by separating and removing the carbohydrates from around the proteins in, for example, soybean meal. This removal is facilitated by the enzymatic hydrolysis of poly- and oligomeric carbohydrates into monosaccharides and other water soluble sugars. The present invention provides for the production of three streams of useful materials. The first is an enriched protein material comparable to the known SPCs but without significant quantities of undigestible oligosaccharides and polysaccharides. The second is an SPI made from the soluble protein in the hydrolysate which is valuable for high-quality feed, food and industrial uses.Type: ApplicationFiled: May 9, 2013Publication date: April 30, 2015Applicant: THE UNIVERSITY OF AKRONInventors: Lu-Kwang Ju, Abdullah Loman, Anthony Coffman, Qian Li, Srujana Koganti
-
Publication number: 20150118212Abstract: The present invention relates to the development of new derivatives of a bacterial plasminogen activator, Staphylokinase (SAK), having one or more amino acid residues with single or multiple cysteines at the amino and/or carboxy terminal ends and their conjugation with PEG (Polyethylene Glycol), resulting in new Staphylokinase derivatives that display altered oligomeric states, enhanced thermal and protease stability and extended plasma half-life. Also included is the cloning and expression in a suitable bacterial host; purification of Staphylokinase derivatives to homogeneity and their chemical modification by integrating a PEG molecule to create new biologically active Staphylokinases having higher protein stability and improved in vivo plasma half life, that may enhance the clinical potential of Staphylokinase in thrombolytic therapy for the treatment of cardiovascular diseases.Type: ApplicationFiled: March 12, 2014Publication date: April 30, 2015Inventors: SATISH SINGH, Kanak Lata Dikshit
-
Patent number: 9017957Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.Type: GrantFiled: May 1, 2007Date of Patent: April 28, 2015Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro KitamuraInventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
-
Publication number: 20150111279Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: December 19, 2014Publication date: April 23, 2015Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20150111788Abstract: The invention provides novel methods and materials for genetic and genomic analysis using single or multiplex isolation of protein-associated nucleic acids, including transposase-assisted chromatin immunoprecipitation (TAM-ChIP) and antibody-oligonucleotide proximity ligation. These methods comprise tagging and isolating chromatin or other protein-associated nucleic acids and using antibody-oligonucleotide complexes that recognize the proteins associated with such nucleic acids.Type: ApplicationFiled: November 23, 2012Publication date: April 23, 2015Inventors: Joseph Fernandez, Mary Anne Jelinek, Brian Stanley Egan
-
Patent number: 9012195Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.Type: GrantFiled: July 17, 2013Date of Patent: April 21, 2015Assignees: Syntaxin, Ltd., Allergan, Inc.Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20150104847Abstract: The present invention provides a method for stabilizing a cholesterol oxidase, a method for preserving a cholesterol oxidase, and a stabilized composition of cholesterol oxidase. A method for stabilizing a cholesterol oxidase and a method for preserving a cholesterol oxidase which comprises allowing the cholesterol oxidase to coexist with an ?-keto acid in an aqueous medium, and, a stabilized composition of cholesterol oxidase which comprises the cholesterol oxidase being allowed to coexist with an ?-keto acid in an aqueous medium. The method for stabilizing a cholesterol oxidase, the method for preserving a cholesterol oxidase, and a stabilized composition of cholesterol oxidase according to the present invention are useful for clinical diagnosis such as metabolic syndrome.Type: ApplicationFiled: April 18, 2013Publication date: April 16, 2015Applicant: KYOWA MEDEX CO., LTD.Inventors: Tomoko Aratake, Kenta Kinjo
-
Publication number: 20150104468Abstract: The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.Type: ApplicationFiled: May 31, 2013Publication date: April 16, 2015Applicant: IRM LLCInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Badry Bursulaya
-
Publication number: 20150104839Abstract: The present invention discloses a powdery lipase preparation which is a granulated material comprising a lipase derived from Rhizopus oryzae and/or a lipase derived from Rhizopus delemar and a soybean powder having a fat content of 5 mass % or more. A lipase activity is improved by using this powdery lipase preparation.Type: ApplicationFiled: December 17, 2014Publication date: April 16, 2015Inventors: Junko SUZUKI, Yoshie Yamauchi, Tamami Manabe, Satoshi Negishi
-
Publication number: 20150104452Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: June 10, 2014Publication date: April 16, 2015Inventors: Tariq Ghayur, Edward B. Reilly, Andrew Phillips, Randy L. Bell, Yingchun Li, Hua Ying, Susan E. Morgan-Lappe, Gillian A. Kingsbury, Jieyi Wang, Suzanne M. Norvell, Junjian Liu
-
Patent number: 9005630Abstract: The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is a targeting unit and the second targeting unit peptide is a FGL-2 C-terminal peptide according to SEQ ID no 1. Provided herein are also uses of said fusion protein as a vaccine for treating shrimp allergy, as well as a vaccine composition and methods of its production.Type: GrantFiled: November 1, 2012Date of Patent: April 14, 2015Assignee: VeterinaerinstituttetInventors: Maaike Maria Barbara Wilhelmina Dooper, Bjarne Bogen, Heidi Ragnhild Myrset
-
Patent number: 9005910Abstract: The purpose is to produce, with high reproducibility, a complex of labeled probes and a carrier, said complex being to be used for detecting and measuring a target substance to be measured with high sensitivity and high stability. The means for accomplishing the purpose is that a label is bound to a probe-water soluble carrier conjugate using specific binding of an avidin compound such as avidin, streptavidin, etc. to biotin, and the binding of the avidin compound to the probe is performed before the binding to the carrier. Namely, after conjugating the avidin compound to a substance which is capable of binding to the target substance, the conjugate is bound to a high-molecule water-soluble carrier to produce a complex of the avidinized probes and the water-soluble carrier. Then the complex of the avidinized probes and the water-soluble carrier is mixed with a biotinylated label.Type: GrantFiled: April 13, 2011Date of Patent: April 14, 2015Assignees: Eiken Kagaku Kabushiki Kaisha, Advanced Life Science Institute, Inc.Inventors: Yoshiyuki Ohiro, Susumu Takayasu
-
Patent number: 8999690Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.Type: GrantFiled: January 27, 2012Date of Patent: April 7, 2015Assignee: AnaSpec IncorporatedInventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang, Xiang Guobing
-
Patent number: 8999321Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: GrantFiled: July 12, 2011Date of Patent: April 7, 2015Assignees: aTyr Pharma, Inc., Pangu BioPharma LimitedInventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
-
Publication number: 20150093800Abstract: The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products.Type: ApplicationFiled: September 5, 2014Publication date: April 2, 2015Inventors: Ekta MAHAJAN, Kapil KOTHARY, Joanna SO, Jay WERBER
-
Publication number: 20150093801Abstract: Compositions and methods are provided that relate to solubilized phospholipids and their use in stabilizing nucleic acid polymerases. For example, a phospholipid with a tail containing at least 8 carbons can be solubilized in the presence of an amphipathic molecule.Type: ApplicationFiled: October 9, 2014Publication date: April 2, 2015Inventors: Donald Johnson, Thomas C. Evans, JR.
-
Publication number: 20150093370Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.Type: ApplicationFiled: December 9, 2014Publication date: April 2, 2015Inventors: Yoram SHECHTER, Matityahu FRIDKIN
-
Publication number: 20150093788Abstract: The present invention provides compositions, methods, and kits for covalently linking nucleic acid molecules. The methods include a strand invasion step, and the compositions and kits are useful for performing such methods. For example, a method of covalently linking double stranded (ds) nucleic acid molecules can include contacting a first ds nucleic acid molecule, which has a topoisomerase linked to a 3? terminus of one end and has a single stranded 5? overhang at the same end, with a second ds nucleic acid molecule having a blunt end, such that the 5? overhang can hybridize to a complementary sequence of the blunt end of the second nucleic acid molecule, and the topoisomerase can covalently link the ds nucleic acid molecules. The methods are simpler and more efficient than previous methods for covalently linking nucleic acid sequences, and the compositions and kits facilitate practicing the methods, including methods of directionally linking two or more ds nucleic acid molecules.Type: ApplicationFiled: October 2, 2014Publication date: April 2, 2015Inventors: Jonathan CHESNUT, Stewart Shuman, Knut Madden, John Heyman, Robert Bennett
-
Publication number: 20150093792Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 24, 2014Publication date: April 2, 2015Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
-
Patent number: 8993276Abstract: Nucleic acid molecules encoding chimeric cellulase polypeptides that exhibit improved cellulase activities are disclosed herein. The chimeric cellulase polypeptides encoded by these nucleic acids and methods to produce the cellulases are also described, along with methods of using chimeric cellulases for the conversion of cellulose to sugars such as glucose.Type: GrantFiled: July 12, 2013Date of Patent: March 31, 2015Assignee: Alliance for Sustainable Energy, LLCInventors: Qi Xu, John O. Baker, Michael E. Himmel
-
Patent number: 8993295Abstract: The present invention provides methods and compositions for treating various diseases through selective killing of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.Type: GrantFiled: July 20, 2007Date of Patent: March 31, 2015Assignee: The General Hospital CorporationInventors: Brian Seed, Jia Liu Wolfe, Glen S. Cho, Chia-Iun Tsai
-
Publication number: 20150087044Abstract: Embodiments of the present disclosure provide compositions including polyhedral mesoporous metal-organic framework including a biomolecule (e.g., enzyme), methods of making these compositions, methods of use, and the like.Type: ApplicationFiled: June 15, 2012Publication date: March 26, 2015Inventors: Shengqian Ma, Li-June Ming, Yao Chen, Vasiliki Lykourinou
-
Publication number: 20150086994Abstract: The present invention provides novel compositions, methods and apparatus for DNA sequencing that can be performed, e.g., in a two-electrode chamber. The present invention also provides a method for sequencing a nucleic acid comprising immobilizing a plurality of complexes comprising a target nucleic acid, a primer nucleic acid, and a polymerase onto a surface, contacting the surface with a plurality of charged particles comprising a nucleotide phosphate by applying an electric field, reversing the electric field to transport unbound charged particles away from the surface, and detecting the incorporation of a nucleotide phosphate into a single molecule of the primer nucleic acid.Type: ApplicationFiled: October 7, 2014Publication date: March 26, 2015Inventors: John G. K. Williams, Jon P. Anderson
-
Publication number: 20150087628Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.Type: ApplicationFiled: April 10, 2013Publication date: March 26, 2015Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
-
Publication number: 20150086998Abstract: Value-assigned solutions having predetermined concentrations of recombinant Lp-PLA2 are described herein. In particular, described herein are solutions of rLp-PLA2 that are stable for an extended period of time. Kits and assays include these calibration solutions, as well as methods of making and using them are described.Type: ApplicationFiled: May 15, 2014Publication date: March 26, 2015Inventors: Thomas D. SCHAAL, Shaoqiu Zhuo
-
Publication number: 20150087045Abstract: The present disclosure includes a crystalline form and a crystal structure of HCV RNA polymerase and HCV RNA polymerase in a complex with an RNA template primer molecule. In other aspects, the disclosure provides methods of using the crystal structures and structural coordinates to identify homologous proteins and to design or identify agents that can modulate the function of the HCV RNA polymerase and HCV RNA polymerase in a complex with an RNA template primer molecule.Type: ApplicationFiled: January 11, 2013Publication date: March 26, 2015Inventors: Thomas E. Edwards, Angela Man Iu Lam, Ralph T. Mosley, Eisuke Murakami
-
Publication number: 20150087046Abstract: A recombinant fusion protein comprising the moieties Band CT is provided. B is a non-spidroin moiety which provides the capacity of selective interaction with an organic target. CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. The fusion protein is not comprising any moiety derived from the repetitive fragment of a spider silk protein.Type: ApplicationFiled: May 2, 2013Publication date: March 26, 2015Applicant: SPIBER TECHNOLOGIES ABInventor: My Hedhammar
-
Patent number: 8986680Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: GrantFiled: April 28, 2011Date of Patent: March 24, 2015Assignees: aTyr Pharma, Inc., Pangu BioPharma LimitedInventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Patent number: 8986681Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: GrantFiled: April 27, 2011Date of Patent: March 24, 2015Assignees: aTyr Pharma, Inc., Pangu BioPharma LimitedInventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Patent number: 8986655Abstract: PSMA ligands, compositions, and methods therefore are disclosed where the ligand is a peptide having the sequence X1X2CVEVX3QNSCX4X5 where X1-X5 are independently a natural or non-natural amino acid or a peptide having the sequence CALCEFLG [SEQ ID NO: 1]. Especially preferred aspects include diagnostic reagents for detection and/or quantification of PSMA in a sample, therapeutic reagents, and diagnostic imaging reagents.Type: GrantFiled: May 19, 2010Date of Patent: March 24, 2015Assignee: The Regents of the University of CaliforniaInventors: Gregory A. Weiss, Jessica Arter, Juan E. Diaz
-
Publication number: 20150079657Abstract: The present disclosure provides compositions and methods for acetylating histones at targeted chromosomal locations in a cell. In particular, the disclosure provides a fusion protein comprising a DNA binding domain and at least one histone acetyltransferase (HAT) domain, such that the DNA binding domain targets the fusion protein to a targeted chromosomal location and the HAT domain acetylates histones at the targeted location.Type: ApplicationFiled: February 28, 2013Publication date: March 19, 2015Applicant: SIGMA-ALDRICH CO. LLCInventors: Qingzhou Ji, Carol Kreader